Informations générales (source: ClinicalTrials.gov)
Tool for Evaluating the Effectiveness of the DENVER Protocol for Attention to Faces (Face) and the Development of Social Communication (Com) in Young Children With Autism Spectrum Disorder (ASD) (FACECOM)
Observational
University Hospital, Grenoble (Voir sur ClinicalTrials)
mai 2024
mai 2028
29 juin 2024
Early remediation of the communicative and social difficulties of children with autism
spectrum disorders (ASD) is central. However, from the age of 6-8 months, children with
ASD show a lack of attention to social stimuli such as faces: such early avoidance
behavior could be at the root of later communicative difficulties (language, attention).
The Denver program aims to stimulate social communication and attention to faces in
children with ASD aged between 18 and 60 months. Although the Denver protocol is
currently recommended by the French National Authority for Health (HAS), the Denver
protocol has not yet been widely used or evaluated in France, mainly due to a lack of
tools adapted to non-verbal populations. The goal of FaceCom is to help clinicians to
evaluate the efficiency of the Denver Protocol.
Etablissements
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Alps-Isere Hospital Center - 38120 - Saint-Égrève - Isere - France | Isabelle Palacios, MD | Contact (sur clinicalTrials) | |||
| Savoie Hospital Center - 73000 - Chambéry - Savoie - France | Marine Goubier, MD | Contact (sur clinicalTrials) | |||
| University Grenoble Alps - 38058 - Grenoble - France | Mathilde FORT, PhD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion criteria for all groups
- native language: French
- oral consent of the child, if able to do so, written consent of 2 parents or legal
guardians
Inclusion criteria for the ASD experimental and control groups:
-ASD Diagnosis The diagnosis of ASD is clinical and is made by the referring physician.
It is based on the DSM 5 and the clinical assessment of each patient.
Inclusion criteria for the ASD experimental group:
- absence of neurological pathology (epilepsy, etc.) and known genetic syndrome on
admission
- written consent of 2 parents or legal guardians
Non-inclusion criteria for all children:
- primary hearing and visual impairment (unless fully corrected).
Non-inclusion criteria for DT children only:
- a known neurodevelopmental, neurological or psychiatric disorder.
- native language: French
- oral consent of the child, if able to do so, written consent of 2 parents or legal
guardians
Inclusion criteria for the ASD experimental and control groups:
-ASD Diagnosis The diagnosis of ASD is clinical and is made by the referring physician.
It is based on the DSM 5 and the clinical assessment of each patient.
Inclusion criteria for the ASD experimental group:
- absence of neurological pathology (epilepsy, etc.) and known genetic syndrome on
admission
- written consent of 2 parents or legal guardians
Non-inclusion criteria for all children:
- primary hearing and visual impairment (unless fully corrected).
Non-inclusion criteria for DT children only:
- a known neurodevelopmental, neurological or psychiatric disorder.